Phase 2 Completed N=47 Randomized Single-blind Treatment

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

Subarachnoid hemorrhage · Subdural Hematoma · Traumatic Brain Injury · Stroke

Source: ClinicalTrials.gov NCT03496545 ↗

Enrolled (actual)

Serious AEs

2.1%

Results posted

Jun 2021

Primary outcomePrimary: Temperature Burden — 37.8; 37.7 Temperature in degrees Celsius

Summary

The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.

Outcome Measures

Outcome	Result	p-value
PRIMARY Temperature Burden	37.8; 37.7	—
SECONDARY Incidence of Adverse Events - Symptomatic Hypotension, Nausea and Headache	12; 17; 2; 3; 8; 12	—
SECONDARY Total Time That Temperature is ≥ 38.3ºC	216; 300	—
SECONDARY Total Time to First Temperature < 37.5ºC	253.5; 556	—

Eligibility Criteria

Inclusion Criteria

age ≥18 years old
weight ≥ 40 kg
one reading of body temperature ≥ 38.3 ºC
diagnosis of subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, subdural hematoma, or ischemic stroke
admission to the Intensive Care Unit at UCSF Medical Center or Zuckerberg San Francisco General Hospital.

Exclusion Criteria

bromocriptine or acetaminophen hypersensitivity or allergy
known contraindication to bromocriptine- known ergot alkaloid hypersensitivity, known history of syncopal migraine
contraindication to nasogastric tube or swallowing pills
current diagnosis of acute liver failure, acute liver injury, or prior diagnosis of cirrhosis. acute presentation ( 300mg less than 1 hour prior to fever presentation.
pregnancy
extracorporeal blood circuit therapies: replacement therapy, extracorporeal life support (ventricular assist device, extracorporeal membrane oxygenation) during study period
anticipated ICU stay < 48 hours'
creatinine clearance ≤ 30
severe cardiovascular disease (especially unstable angina or severe valvular disease)
patients already taking bromocriptine for other indications

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03496545). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.